Drug intelligence / Profile preview

HR20014

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

HR20014 is a recombinant polypeptide drug under development for the treatment of diabetes mellitus. It acts as a modulator of the insulin receptor (INSR), targeting metabolic and endocrine disorders. The drug is administered subcutaneously and has been evaluated in phase 1 clinical trials to assess its pharmacokinetics, pharmacodynamics, and safety profile in healthy subjects. Jiangsu Hengrui Pharmaceuticals is both the originator and active developer of this agent[1][3][7].

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on HR20014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR20014.

Explore the full profile